Morepen Laboratories Completes First Dispatch Under ₹825 Crore CDMO Mandate
Gurugram, Haryana, July 1, 2026 — Morepen Laboratories Limited has successfully completed its first commercial dispatch under a substantial ₹825 crore Contract Development and Manufacturing Organization (CDMO) mandate. This initial dispatch, valued at approximately ₹50 crore, was executed during the first quarter of FY2026-27, marking the successful transition of the mandate from the validation and qualification stage to active commercial execution.Morepen Laboratories Limited, which holds NSE: MOREPENLAB and BSE: 500288 listings, confirmed the milestone, strengthening its position in global manufacturing partnerships.
Commenting on this development, Mr. Sanjay Suri, Managing Director of Morepen Laboratories Limited, stated that the achievement is a key milestone in the company’s transition toward long-duration global manufacturing partnerships. He noted that the teams had worked closely with the customer through validation, supply chain planning, and manufacturing readiness. With commercial supplies now underway, the company is focused on scaling up, expanding capacity, and developing its CDMO platform across additional product and customer opportunities.
Future Growth and Capacity Expansion
The commencement of commercial supplies under this mandate reinforces Morepen’s strategy to build a scalable CDMO platform and deepen customer partnerships for long-duration global manufacturing engagements.Following the completion of the initial batch, Morepen anticipates scaling up the program in the subsequent quarter. The company expects additional supplies amounting to approximately ₹225 crore during Q2FY2026-27, subject to regulatory requirements and customer schedules.
To support growing CDMO opportunities, the company is actively strengthening its manufacturing infrastructure. Total reactor capacity is projected to reach around 600 KL by the end of Q2. Subsequent phases include further expansion toward 800 KL and 1,000 KL.
Morepen Laboratories Limited is a pharmaceutical and healthcare company operating in APIs, finished formulations, diagnostics, and consumer healthcare products. The company continues to strengthen its manufacturing, research, and regulatory capabilities to support growth across international and domestic markets.
MOREPENLAB Stock Price Movement
On Wednesday, Morepen Laboratories Limited stock rallied in the market, closing at ₹62.68 after gaining 6.26% from the previous close. The shares saw a solid trading session as volume climbed to nearly 39.7 million.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.